Latest Anticonvulsants Stories
Now the Only Extended-Release Topiramate Product for Initial Monotherapy in Patients Two Years and Older with Partial-Onset Seizures or Primary Generalized Tonic-Clonic Seizures MAPLE GROVE,
WOODCLIFF LAKE, N.J., April 30, 2015 /PRNewswire/ -- Eisai Inc. and Eisai Co., Ltd.
Studies Demonstrate Favorable Long-Term Safety Profile for Qudexy(TM) XR and Explore its Usefulness for Patients with Swallowing Difficulties WASHINGTON, April 21, 2015 /PRNewswire/ --
BRUSSELS, April 20, 2015 /PRNewswire/ -- UCB, a global biopharmaceutical company focusing on neurology and immunology treatment and research, is sponsoring a total of 24 data presentations at the 67(th)
The approval letter allows clinical development of DP-VPA through Phase 3 for epilepsy REHOVOT, Israel, April 14, 2015 /PRNewswire/ -- D-Pharm Ltd., (TASE: DPRM)
- June re-launch with significantly expanded commercial resources NEWARK, Calif., April 2, 2015 /PRNewswire/ -- Depomed, Inc.
DALLAS, March 4, 2015 /PRNewswire/ -- RnRMarketResearch.com adds "Epilepsy - Pipeline Review, H1 2015" therapeutic market research report of 330 pages with latest updates,
WOODCLIFF LAKE, N.J., Feb.
Free Trial Offer, Co-Pay Program and Prior Authorization Assistance Now Available MAPLE GROVE, Minn., Feb.
- Major milestone for brivaracetam is latest step towards UCB goal of extending treatment choices for adult epilepsy patients with uncontrolled partial-onset seizures BRUSSELS, Jan.
- The parings of haberdine; also, any kind of fragments.